|Trial status||Trial open for recruitment|
Prospective observational study
|Inclusion criteria||patients that have initiated reimbursed ibrutinib therapy on or after its launch (via the eHealth procedure) or participated in the Medical Need Program for CLL or MCL and switched to reimbursed ibrutinib on or after 1 August 2015 or had started treatment|
The New Jules Bordet Institute, located on the university campus of the ULB in Anderlecht, is ready and will soon welcome its first patients. A new state-of-the-art hospital entirely dedicated to the fight against cancer.